The off-label use of medicines is a routine clinical practice oncology, especially in malignant-tumour patients with no treatment alternatives left when registered-drug options have been exhausted or standard therapies reveal contraindications. recent shift from single-gene assays to multigene panels powered by full-exome -genome sequencing expands the capacity precision therapy, leading wider ...